Publication:
QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer

Simple item page
dc.contributor.authorKOCAKAYA, DERYA
dc.contributor.authorsDemircan, Nazim Can; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Kocakaya, Derya; Sahin, Ahmet Anil; Ercelep, Ozlem; Dane, Faysal; Yumuk, Perran Fulden
dc.date.accessioned2022-03-12T22:40:45Z
dc.date.available2022-03-12T22:40:45Z
dc.date.issued2020
dc.description.abstractAfatinib improves survival in metastatic non-small-cell lung cancer driven by activating epidermal growth factor receptor mutations. QT interval prolongation is a possible side effect of tar geted anticancer drugs, but this has not been reported before with afatinib. We report a case of metastatic pulmonary adenocarcinoma with epidermal growth factor receptor exon 19 deletion who was treated with first-line afatinib. The patient was started on afatinib with a total dose of 40 mg/day and experienced grade 3 (> 500 ms) QT interval prolongation in the seventh week. Dose was interrupted and then reduced to 30 mg/day after the event repeated. QT prolongation occurred only once with the reduced dose and radiologic oligoprogression was detected. Local therapy was performed and afatinib was continued as 30 mg/day. To the best of our knowledge, this case marks the first QT interval prolongation associated with afatinib. It is prudent to perform a baseline cardiologic evaluation and electrocardiogram monitoring in non-small cell lung cancer patients treated with this drug. (c) 2020 Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.currproblcancer.2020.100594
dc.identifier.eissn1535-6345
dc.identifier.issn0147-0272
dc.identifier.pubmed32505368
dc.identifier.urihttps://hdl.handle.net/11424/236014
dc.identifier.wosWOS:000594997700011
dc.language.isoeng
dc.publisherMOSBY-ELSEVIER
dc.relation.ispartofCURRENT PROBLEMS IN CANCER
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAfatinib
dc.subjectEpidermal growth factor receptor
dc.subjectNon-small-cell lung cancer
dc.subjectQT prolongation
dc.subjectTyrosine kinase inhibitor
dc.subjectOPEN-LABEL
dc.subjectCARDIOTOXICITY
dc.subjectADENOCARCINOMA
dc.subjectCHEMOTHERAPY
dc.titleQT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.id18e0036f-ab24-4a39-a722-22826d516e9f
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber100594
local.journal.numberofpages6
local.journal.quartileQ3
oaire.citation.issue6
oaire.citation.titleCURRENT PROBLEMS IN CANCER
oaire.citation.volume44
relation.isAuthorOfPublication2771cdd6-7c3b-45a8-89fe-a429a2950516
relation.isAuthorOfPublication.latestForDiscovery2771cdd6-7c3b-45a8-89fe-a429a2950516

Files

Collections

Research Outputs